Proglumetacin_product_DataBase

Bioactivity	Proglumetacin is an orally active and potent cyclo-oxygenase inhibitor. Proglumetacin can inhibits SARS-CoV Mpro (main protease of the SARS-CoV-2), with an AC50 of 8.9 μM (activity concentration at half maximal activity). Proglumetacin has anti-inflammatory activity, can be used for inflammation (such as Rheumatoid arthritis, and Allergic air pouch inflammation) research[1][2][3].
Invitro	Proglumetacin strongly inhibits 5-HETE formation, with an IC50 of 1.5 μM[2].Proglumetacin inhibits leukocyte migration by inhibiting the production of the chemotactic cyclo-oxygenase product thromboxane B2[2].
In Vivo	Proglumetacin (Sprague-Dawley rats, 0-30 mg/kg, Orally, once) dose-dependently inhibits accumulation of pouch exudate[1]. Animal Model:
Name	Proglumetacin
CAS	57132-53-3
Formula	C46H58ClN5O8
Molar Mass	844.43
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. NaohikoOno, et al. Effects of proglumetacin maleate and its major metabolites on allergic air pouch inflammation in rats. Eur J Pharmacol. 1987;142(2):245-251. [2]. Ono N, et al. Pharmacological studies on proglumetacin maleate, a new non-steroidal anti-inflammatory drug (4). Mode of action on anti-inflammatory activity. Japanese Journal of Pharmacology, 1986, 42(3):431-9. [3]. Alves VM, et al. QSAR Modeling of SARS-CoV Mpro Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2. Mol Inform. 2021 Jan;40(1):e2000113. [4]. Bozsoky S, Zahumenszky Z. A 3-month, double-blind study of proglumetacin and naproxen in the treatment of rheumatoid arthritis. Curr Med Res Opin. 1982;8(2):89-96.

PeptideDB

Proglumetacin

CAS: 57132-53-3 F: C46H58ClN5O8 W: 844.43